Results 171 to 180 of about 34,322 (240)

Diffuse CD30‐Positive Cutaneous Infiltrate in a Clinically Suspected Hidradenitis Suppurativa Lesion: Histopathologic and Diagnostic Challenges

open access: yesJournal of Cutaneous Pathology, Volume 53, Issue 9, Page 809-814, September 2026.
ABSTRACT Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder affecting apocrine gland–bearing areas. We report a 38‐year‐old male with a lesion in the left axilla, initially clinically interpreted as HS and resistant to antibiotics.
R. Gervasi   +10 more
wiley   +1 more source

Case Report: Safety and efficacy of combination therapy with adalimumab and anakinra in two patients with severe inflammatory diseases. [PDF]

open access: yesFront Pediatr
Coslovich S   +8 more
europepmc   +1 more source

Outcomes of Root Canal Treatment in Patients With Autoimmune Disease: A Retrospective Case–Control Study

open access: yesInternational Endodontic Journal, Volume 59, Issue 9, Page 1831-1840, September 2026.
ABSTRACT Aim The purpose of this study was to compare the outcome of nonsurgical root canal treatment (RCT) in patients with autoimmune diseases (AD) with the outcome in patients without AD. The null hypothesis was: there is no difference in the outcomes of RCT regardless of the patient group. Results were also compared among AD subgroups: inflammatory
Seoyeon Lee   +4 more
wiley   +1 more source

Efficacy and Safety of Adalimumab as Monotherapy Versus Adalimumab With Methotrexate for Psoriasis: A Systematic Review. [PDF]

open access: yesCureus
Alanazi AF   +8 more
europepmc   +1 more source

Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor‐Induced Autoimmunity

open access: yesACR Open Rheumatology, Volume 8, Issue 8, August 2026.
The rapid integration of immune checkpoint inhibitors (ICIs) into standard oncology protocols has birthed a new frontier in clinical rheumatology: immune‐related adverse events (irAEs). By disrupting the programmed cell death‐1 (PD‐1)/PD‐L1 and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) axes to restore antitumor T cell activity, these ...
Xizi Hu   +3 more
wiley   +1 more source

Model-Based Design of Sustained-Release Formulations of Anti-TNF-α Monoclonal Antibodies for Intravitreal Administration. [PDF]

open access: yesPharmaceutics
Reig-López J   +5 more
europepmc   +1 more source

B‐Cell Depletion Relative to Tumor Necrosis Factor Inhibition Extends the Duration of Viral Shedding in COVID‐19 Among Autoimmune Disease Patients: A Matched Prospective Cohort Study

open access: yesACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective To investigate SARS‐CoV‐2 viral shedding duration in autoimmune patients using B cell depleting (BCD) therapy or tumor necrosis factor inhibitors (TNFi) and immunocompetent comparators. Methods We conducted a matched cohort analysis among participants in POSITIVES, a prospective study enrolling outpatients with acute COVID‐19 within five days
Liya Sisay Getachew   +34 more
wiley   +1 more source

Home - About - Disclaimer - Privacy